Description of Invention:
The human immunodeficiency virus (HIV) is the causative agent of acquired immunodeficiency syndrome (AIDS). Drug-resistance is a critical factor contributing to the gradual loss of clinical benefit to treatments for HIV infection. Accordingly, combination therapies have further evolved to address the mutating resistance of HIV. However, there has been great concern regarding the apparent growing resistance of HIV strains to current therapies.
The present invention provides for a novel family of thioesters and uses thereof. These thioesters are capable of inactivating viruses by a variety of mechanisms, particularly by complexing with metal ion-complexing zinc fingers. The invention further provides for methods for inactivating a virus, such as the human immunodeficiency virus (HIV), using these compounds, and thereby also inhibiting transmission of the virus.
Inventors:
James A. Turpin (NCI) Yongsheng Song (NCI) John K. Inman (NIAID) Mingjun Huang (NCI) Anders Wallqvist (NCI) David G. Covell (NCI) William G. Rice (NCI) Ettore Appella (NCI) et al.
Patent Status:
DHHS Reference No. E-136-1998/0 --
U.S. Patent No. 6,706,729 issued 16 Mar 2004
U.S. Patent Application No. 10/738,062 filed 16 Dec 2003
Licensing Status: Available for non-exclusive or exclusive licensing.
For Additional Information Please Contact: Sally Hu PhD MBA
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301) 435-5606
Email: hus@mail.nih.gov
Fax: (301) 402-0220
